NASDAQ$ANNX
Annexon Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Annexon reported second quarter 2024 financial results and highlighted portfolio progress.
Annexon reported a net loss of $29.6 million, or $0.23 per share, for the quarter ended June 30, 2024. The company's cash, cash equivalents, and short-term investments totaled $368.7 million as of June 30, 2024, which is expected to fund operations into the second half of 2026.
- ANX005 significantly accelerated recovery of GBS patients vs. placebo in Phase 3 trial.
- Dosing initiated in ARCHER II registrational trial for ANX007.
- First-in-Kind Oral C1s Inhibitor ANX1502 Successfully Completed Bridging Study.
- The company anticipates topline data by year-end 2024 for the real-world evidence comparability study for ANX005 in GBS.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$0
Forward guidance
Annexon anticipates several key catalysts over the next 24 months across its flagship programs, with the potential to drive significant benefit for millions of patients and shareholders.
Tailwinds
- Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025 for ANX005 in GBS.
- Phase 3 ARCHER II trial topline data expected in the second half of 2026 for ANX007 in GA.
- Plans for an injection-controlled study, ARROW, to assess the prevention of ≥15-letter loss of BCVA, are also ongoing for ANX007 in GA.
- POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 for ANX1502 in CAD.
- Cash, cash equivalents and short-term investments were $368.7 million as of June 30, 2024, expected to be sufficient to fund the company’s planned operating expenses into the second half of 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro